appended

below. A pair of biostatisticians' questions about a prominent genetics group at Duke University have not only raised doubts about a popular method of tumor analysis but also led to accusations that a cancer researcher had padded his resumé. Clinical trials at Duke based on these methods have been suspended, Duke is investigating the researcher in question, and there are calls for a general review of the field. Full story at 2 / 614? sa_campaign = Email/sntw/6-August-2010/10.1126 / science.329.5992. 614

To work with dangerous pathogens such as anthrax, US researchers must follow strict rules governing so-called select agents, or potential bioweapons. But what about a DNA sequence ordered from a company that contains some of the genes that make anthrax deadly? Currently, such an entity-or an artificial organism designed with such DNA-would not be subject to the same regulations despite its potential as a bioweapon, simply because of the way select agents are defined. A report by the National Academies this week recommends plugging this loophole with a new system of defining select agents based on DNA sequences. Full story at 2 / 615? sa_campaign = Email/sntw/6-August-2010/10.1126 / science.329.5992.615